Piper Jaffray analyst JP McKim noted that the FDA website shows that Dexcom got 510K approval for an "integrated continuous glucose monitoring system for non-intensive diabetes management" and said the number one question he got was if this was the Verily product. He thinks a newly released summary document implies that it is not, but instead a product specific for those without significant risk of hypoglycemia. McKim, who expects to hear a lot more on the company's earnings call tomorrow night, said that "what is clear is that [Dexcom] is making moves." He sees the earnings call tomorrow night setting up for a lot of new updates that he thinks will be positively received and keeps an Overweight rating and $150 price target on Dexcom ahead of the event.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here

Canaccord analyst William Plovanic raised the firm's price target on DexCom to $145 from $144 and keeps a Buy rating on the shares. The firm said they reported a slight;ly better than expected Q1 as the company raised the low-end and mid-point of its revenue guidance and reiterated its adjusted GM/OM/EBITDA margins for 2024.

Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSSnap (SNAP) up... To see the rest of the story go to thefly.com. See Story Here

Pre-earnings options volume in DexCom is 11.4x normal with calls leading puts 11:2. Implied volatility suggests the market is anticipating a move near 5.8%, or $8.05, after results are released. Median move over the past eight quarters is 5.4%.